Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV004667693 | SCV005169148 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-05-15 | criteria provided, single submitter | clinical testing | The p.E1615G variant (also known as c.4844A>G), located in coding exon 33 of the SMARCA4 gene, results from an A to G substitution at nucleotide position 4844. The glutamic acid at codon 1615 is replaced by glycine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear. |
| Labcorp Genetics |
RCV005103449 | SCV005785785 | uncertain significance | Rhabdoid tumor predisposition syndrome 2 | 2024-10-28 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 1615 of the SMARCA4 protein (p.Glu1615Gly). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SMARCA4 protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |